| Market Capitalization (Millions $) |
1,530 |
| Shares
Outstanding (Millions) |
163 |
| Employees |
749 |
| Revenues (TTM) (Millions $) |
596 |
| Net Income (TTM) (Millions $) |
-88 |
| Cash Flow (TTM) (Millions $) |
-46 |
| Capital Exp. (TTM) (Millions $) |
6 |
Business Description
Novavax Inc.
is a clinical-stage biotechnology company that specializes in the development of vaccines to prevent infectious diseases.
The company is headquartered in Gaithersburg, Maryland, and was founded in 1987.
Novavax's focus is on developing novel recombinant protein nanoparticle vaccines using its proprietary technology platform, Matrix-M.
Matrix-M is a proprietary saponin adjuvant that stimulates the immune system and enhances the efficacy of vaccines.
Novavax has used this adjuvant to develop vaccines for a variety of infectious diseases, including influenza, respiratory syncytial virus (RSV), COVID-19, and Ebola.
Novavax's lead product candidate, NVX-CoV2373, is a COVID-19 vaccine that uses Matrix-M to enhance the immune response to the SARS-CoV-2 spike protein.
The vaccine is administered in two doses, 21 days apart, and has shown high levels of efficacy in clinical trials conducted in the UK and South Africa.
Novavax has partnered with several organizations to develop and distribute its vaccines globally.
In the US, the company has received funding from the US Department of Defense, the National Institutes of Health, and the Coalition for Epidemic Preparedness Innovations (CEPI).
Overall, Novavax Inc is a biotechnology company that is pioneering the use of recombinant protein nanoparticle vaccines, with its proprietary Matrix-M technology.
The company has a strong pipeline of vaccines and partnerships with several organizations for global distribution.
Company Address: 21 Firstfield Road, Gaithersburg, 20878
Company Phone Number: 268-2000 Stock Exchange / Ticker: NASDAQ NVAX
|
5.16% 
30.25 %